The effectiveness of leflunomide in psoriatic arthritis

Clinical and Experimental Rheumatology

Volumn 32, Issue 5, 2014, Pages 728-731

  Asiri, Alhussain ^a,b   Thavaneswaran, Arane ^b   Kalman Lamb, Gideon ^b   Chandran, Vinod ^b   Gladman, Dafna D ^b  

^a KING KHALID UNIVERSITY   (Saudi Arabia)

^b TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Leflunomide; Psoriatic arthritis; Treatment

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLD; LEFLUNOMIDE; METHOTREXATE; RETINOID; SALAZOSULFAPYRIDINE; STEROID; IMMUNOSUPPRESSIVE AGENT; ISOXAZOLE DERIVATIVE;

ALOPECIA; ARTICLE; CANADA; COHORT ANALYSIS; DATA ANALYSIS; DATA BASE; DIARRHEA; DISEASE DURATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; OBSERVATIONAL STUDY; PATIENT IDENTIFICATION; PREDICTIVE VALUE; PSORIATIC ARTHRITIS; TREATMENT DURATION; UNIVERSITY HOSPITAL; ADULT; ARTHRITIS, PSORIATIC; DRUG COMBINATION; MIDDLE AGED; PROSPECTIVE STUDY; REMISSION; RISK; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

ADULT; ARTHRITIS, PSORIATIC; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; LOGISTIC MODELS; MALE; METHOTREXATE; MIDDLE AGED; ODDS RATIO; ONTARIO; PROSPECTIVE STUDIES; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84907585310     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Bruce IN: Psoriatic arthritis: clinical features. In: Hochberg M, SILMAN A, Smolen J, Weinblatt ME, Weisman M (Eds.) Rheumatology. 3rd ed. Philadelphia: Mosby, 2003:1241-52.
2. Shbeeb M, Uramoto KM, Gibson LE, O'Fallon WM, Gabriel SE.: The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol 2000; 27: 1247-50.
3. Goodfield M.: Skin lesions in psoriasis. Baillieres Clin Rheumatol 1994; 8: 295-316.
4. Tassiulas I, Duncan SR, Centola M, Theofilopoulos AN, BOUMPAS DT.: Clonal characteristics of T cell infiltrates in skin and synovium of patients with psoriatic arthritis. Hum Immunol 1999; 60: 479-91.
5. Costello PJ, Winchester RJ, Curran SA et al.: Psoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clonal expansions that appear antigen driven. J Immunol 2001; 166: 2878-86.
6. NickoloffBJ, Wrone-Smith T.: Injection of pre-psoriatic skin with CD4_ T cells induces psoriasis. Am J Pathol 1999; 155: 145-58.
7. Steiner G, Tohidast-Akrad M, Witzmann G et al.: Cytokine production by synovial T cells in rheumatoid arthritis. Rheumatology (Oxford) 1999; 38: 202-13.
8. Mease P. Psoriatic arthritis and spondyloarthritis assessment and management update. Curr Opin Rheumatol 2013; 25: 287-96.
9. Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens F, Jones P.: Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis. Arthritis Rheum 2004; 50: 1939-50.
10. Black RL, O'brien WM, Van Scott EJ, Auerbach R, Eizen AZ, Bunim J.: Methotrexate therapy in psoriatic arthritis. JAMA 1964; 189: 743-7.
11. Jones G, Crotty M, Brooks P.: Interventions for treating psoriatic arthritis (Cochrane Review). In: The Cochrane Library, Issue 3. Oxford: Update Software; 2001.
12. BROCKBANK J, GLADMAN D.: Diagnosis and management of psoriatic arthritis. Drugs 2002; 62: 2447-57.
13. Griffiths CE, Clark CM, Chalmers RJ, LI WAN PO A, Williams HC.: A systematic review of treatments for severe psoriasis. Health Technol Assess 2000; 4:1-125.
14. Breedveld FC, Dayer J-M.: Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 2000; 59: 841-9.
15. Smolen JS, Kalden JR, Scott DL et al.: Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomized, multicentre trial. Lancet 1999; 353: 259-66.
16. Strand V, Cohen S, SchiffM et al.: Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999; 159: 2542-50.
17. Emery P, Breedveld FC, Lemmel EM et al.: A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000; 39: 655-65.
18. Cohen S, Cannon GW, SchiffM et al.; for the Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group: Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Arthritis Rheum 2001; 44: 1984-92.
19. ScotT DL, Smolen JS, Kalden JR et al.: Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis 2001; 60: 913-23.
20. van der Heijde D, Kalden J, Scott D, Smolen J, Strand V.: Long term evaluation of radiographic disease progression in a subset of patients with rheumatoid arthritis treated with leflunomide beyond 2 years. Ann Rheum Dis 2004; 63: 737-9.
21. Liang GC, Barr WG.: Open trial of leflunomide for refractory psoriasis and psoriatic arthritis. J Clin Rheumatol 2001; 7: 366-70.
22. Reich K, Hummel KM, Beckmann I, Mossner R, neumann C.: Treatment of severe psoriasis and psoriatic arthritis with leflunomide. Br J Dermatol 2002; 146: 335-6.23.
23. Cuchacovich M, Soto L.: Leflunomide decreases joint erosions and induces reparative changes in a patient with psoriatic arthritis. Ann Rheum Dis 2002; 61: 942-3.
24. Behrens F, Finkenwirth C, Pavelka K et al.: Leflunomide in psoriatic arthritis: results from a large European prospective observational study. Arthritis Care Res (Hoboken) 2013; 65: 464-70.
25. Gladman DD, Shuckett R, Russell ML et al.: Psoriatic arthritis (PSA) - an analysis of 220 patients. Q J Med 1987; 62: 127-41.
26. Taylor W, Gladman D, Helliwell P Marchesoni A, Mease P, Mielants H.: Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54: 2665-73.
27. Fredriksson T, Pettersson U.: Severe psoriasis: oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44.
28. Dougados M, Emery P, Lemmel EM et al.: Efficacy and safety of leflunomide and predisposing factors for treatment response in patients with rheumatoid arthritis: RELIEF 6-month data. J Rheumatol 2003; 30: 2572-9.
29. Osiri M, Shea B, Robinson V et al.: Leflunomide for the treatment of rheumatoid arthritis: a systematic review and meta-analysis. J Rheumatol 2003; 30: 1182-90.
30. Weinblatt ME, Kremer JM, Coblyn JS et al.: Pharmacokinetics, safety and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999; 42: 1322-8.
31. Kavanaugh A: Psoriatic arthritis: treat-totarget. Clin Exp Rheumatol 2012; 30 (Suppl. 73): S123-5.
32. Cortesi PA, Scalone L, D'angiolella L et al.: Systematic literature review on economic implications and pharmacoeconomic issues of psoriatic arthritis. Clin Exp Rheumatol 2012; 30 (Suppl. 73): S126-31